Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molar Potency Study of HM12460A vs Insulin Glargine
NCT03330314Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Oct 2017
- Primary completion
- Feb 2018
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of HM12460A in diabetes mellitus (DM) (4 arms), sponsored by Hanmi Pharmaceutical. Primary endpoint: Blood glucose assessment of HM12460A and insulin glargine at 1 month. Started Oct 2017; status: completed.
02
Drugs
HM12460A
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT03330314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03330314.